Glucagon-like Peptide Drugs: Mechanisms and Health Effects [Study 219 - 226 Analysis]
Physionic
Jan 24, 2024
Episode description
*JOIN THE PHYSIONIC INSIDERS [PREMIUM CONTENT]*
Join the Physionic Insiders: https://bit.ly/PhysionicInsiders2
*HEALTH AUTONOMY [COURSE]*
Learn to Analyze & Apply Studies for Yourself: https://bit.ly/healthautonomy
*JOIN THE COMMUNITY*
Join my Community [It’s Free!]: https://bit.ly/PhysionicCommunity2
*EMAIL LIST*
1-2 Weekly Email of Value [It’s Free!]: http://bit.ly/2AXIzK6
*HIRE ME FOR CONSULTING:*
Consulting: https://bit.ly/3dmUl2H
Created with Biorender
Studies, Notes, & Amendments: https://bit.ly/PhysionicGLP1A
0:00 - Introduction
1:40 - All Topics Covered
2:36 - Mechanisms of Action
24:07 - GLP1A on Health Markers
24:15 - Study 223
27:47 - Body Weight [and how to read the data]
35:37 - Heart Rate
36:35 - Blood Pressure
37:08 - Low Density Lipoproteins (LDL-Cholesterol)
38:48 - Glycated Hemoglobin (HbA1C)
45:03 - GLP1A on Mortality
45:20 - Mortality
49:09 - Side Effects
52:46 - Mid-Point Conclusions/Take Aways
********CRITIQUES, RULES, AND NOTES********
Be aware of the following rules before posting comments:
- Please do not post summaries of the video in the comments - it damages retention on the video and YouTube is less likely to promote it (these videos cost me a lot of money to produce).
Critiques of my work are welcome! Please be aware of the following notes & rules before submitting critique:
The information provided in this study analysis is limited to the subject and outcomes detailed in the study analyzed [For example: “Consuming sugar (subject) raises insulin (outcome).”] and is not meant to be an all-encompassing education on every health outcome of the subject (unless otherwise stated). I welcome all respectful critique of the study as I may have missed a key detail that you may catch; if that is the case, I will make an ‘Amendment’ to the video and credit you (thank you for making science knowledge better!). Also be aware that I receive hundreds of YouTube comments per day, so the only way your critique can be considered is if you follow the steps outlined below. Finally, YouTube auto-deletes links, so I do not see most comments with links attached.
RULES:
If your comment is rude, you will be banned.
If your comment is not about the studies/topics at hand (i.e. extending to other outcomes not discussed) or offers critique with no scientific basis, it is unlikely to receive a response.
If you can follow these rules, I will try to address your critique and if there is merit, I will add an AMENDMENT to the content in question and pin it so everyone can see it.
Please use the following link to submit your critique: https://bit.ly/PhysionicCritique
Disclaimer: None of the information provided by this brand is a replacement for your physician's advice. This brand is information for the sake of knowledge and the options of choice it provides, not in any way a personalized prescription. Please consult your physician before making any health related changes.
#wegovyweightloss #ozempicweightloss #glp1
Mindsip insights from this episode:
Utilize GLP-1 agonists for safe insulin release management
GLP-1 agonists only stimulate significant insulin release when blood sugar is already elevated, which acts as a failsafe to prevent hypoglycemia.
Hack brain hunger signals to control food intake
In the brain, GLP-1 agonists make neurons that inhibit food intake more likely to activate while making neurons that encourage food intake less likely to activate.
Understand GLP-1 agonist drugs' longevity through enzyme resistance
GLP-1 agonist drugs are slightly modified versions of the natural hormone, making them resistant to the enzyme that normally degrades the body's own GLP-1 within minutes.
Monitor heart rate changes with GLP-1 agonists despite blood pressure reduction
While they lower blood pressure, studies show GLP-1 agonists also cause a small but statistically significant increase in resting heart rate.
Leverage GLP-1 agonists for gradual mortality risk reduction
The 11% relative risk reduction in mortality from GLP-1 agonists translates to a smaller ~1% absolute risk reduction over at least one year, a benefit expected to grow over time.
Challenge claims of muscle loss from GLP-1 agonists with scientific scrutiny
Despite anecdotes, there is currently no controlled scientific data from studies proving that GLP-1 agonists cause muscle loss.
Utilize GLP-1 agonists to enhance satiety and reduce appetite
GLP-1 agonists slow the opening of the stomach's pyloric sphincter, keeping food in the stomach longer and prolonging the feeling of fullness.
More from
Physionic
This New Protein Study just Changed how we Think about Protein!
The One Breakfast Food that Eliminates Fat, Protects the Liver, and Builds Muscle!
The Liver Effect of using Wegovy and Ozempic that Researchers Didn’t Expect
The Crunchy Add-On Linked to Less Visceral Fat and Preserving your Brain
It Crushes Visceral Fat, But the Scale Barely Moves!
